- Home
- GENK vs ASBP Comparison
GENK vs ASBP Comparison
Compare GENK & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- ASBP
- Stock Information
- Founded
- GENK 2011
- ASBP 2021
- Country
- GENK United States
- ASBP United States
- Employees
- GENK N/A
- ASBP N/A
- Industry
- GENK Restaurants
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- ASBP Health Care
- Exchange
- GENK Nasdaq
- ASBP Nasdaq
- Market Cap
- GENK 16.3M
- ASBP 18.7M
- IPO Year
- GENK 2023
- ASBP N/A
- Fundamental
- Price
- GENK $3.00
- ASBP $0.39
- Analyst Decision
- GENK Strong Buy
- ASBP
- Analyst Count
- GENK 2
- ASBP 0
- Target Price
- GENK $7.00
- ASBP N/A
- AVG Volume (30 Days)
- GENK 61.8K
- ASBP 4.1M
- Earning Date
- GENK 11-12-2025
- ASBP 11-24-2025
- Dividend Yield
- GENK 4.00%
- ASBP N/A
- EPS Growth
- GENK N/A
- ASBP N/A
- EPS
- GENK N/A
- ASBP N/A
- Revenue
- GENK $216,137,000.00
- ASBP N/A
- Revenue This Year
- GENK $12.35
- ASBP N/A
- Revenue Next Year
- GENK $14.62
- ASBP N/A
- P/E Ratio
- GENK N/A
- ASBP N/A
- Revenue Growth
- GENK 10.67
- ASBP N/A
- 52 Week Low
- GENK $2.65
- ASBP $0.20
- 52 Week High
- GENK $10.33
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- GENK 47.33
- ASBP 52.23
- Support Level
- GENK $2.90
- ASBP $0.37
- Resistance Level
- GENK $3.12
- ASBP $0.47
- Average True Range (ATR)
- GENK 0.18
- ASBP 0.06
- MACD
- GENK 0.02
- ASBP 0.01
- Stochastic Oscillator
- GENK 52.38
- ASBP 56.40
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.